Avantax Planning Partners’s Cellectis CLLS Stock Holding History

Avantax Planning Partners’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-204	Closed	-$6K	–	443
2018 Q3	$6K	Buy	+204	New	+$5.86K	﹤0.01%	1016

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Avantax Planning Partners's CLLS Position: Q4 2018 in Review

Avantax Planning Partners sold out of Cellectis (CLLS) in Q4 2018, closing a stake of 204 shares — an estimated $6K sold.

Avantax Planning Partners first reported a position in CLLS in Q3 2018 and held it in 1 quarter. The position peaked at $6K in Q3 2018. 65 funds tracked by Wall St. Rank hold CLLS as of Q4 2018.

Avantax Planning Partners reported no remaining Cellectis position as of Q4 2018 after selling out during the quarter.
Avantax Planning Partners sold 204 Cellectis shares in Q4 2018, an estimated $6K.
Avantax Planning Partners first reported a position in Cellectis in Q3 2018 and held it in 1 quarter.
Avantax Planning Partners's Cellectis position peaked at $6K in Q3 2018.
65 funds tracked by Wall St. Rank held Cellectis as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.